<?xml version="1.0" encoding="UTF-8"?>
<SubmissionLabel drug="ZIRGAN">
  <Text>
    <Section id="S1" name="adverse reactions">    6 ADVERSE REACTIONS

  Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).



   EXCERPT:   Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). (  6  )



   To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb at 1-800-323-0000 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  



 
</Section>
    <Section id="S2" name="warnings and precautions">    5 WARNINGS AND PRECAUTIONS



   EXCERPT:    *    ZIRGAN is indicated for topical ophthalmic use only. (  5.1  ) 
 *    Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN. (  5.2  ) 
    
 

   5.1 Topical Ophthalmic Use Only



  ZIRGAN is indicated for topical ophthalmic use only.



    5.2 Avoidance of Contact Lenses



  Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="4" />
    <IgnoredRegion len="26" name="heading" section="S2" start="4" />
    <IgnoredRegion len="241" name="excerpt" section="S2" start="36" />
    <IgnoredRegion len="319" name="excerpt" section="S1" start="190" />
    <IgnoredRegion len="31" name="heading" section="S2" start="284" />
    <IgnoredRegion len="31" name="heading" section="S2" start="381" />
  </IgnoredRegions>
  <Mentions>
    </Mentions>
</SubmissionLabel>